Kenneth Walters, MD
Pulmonary Disease · Anderson, SCNPI 1366679458
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $61,825 of the $80,526 with a category attached, or 76.8%. AstraZeneca accounts for 83.3% of it on its own, with 59 other manufacturers making up the rest. Among pulmonary disease clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 506 payments — averaging $159.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$67K
- Intuitive Surgical$7K
- GSK$1K
- Boehringer Ingelheim$784
- Actelion Pharmaceuticals US, Inc.$331
- Merck$323
- plus $4K from 54 others
What the payments were for
- Speaking & faculty fees$61,82577%
- Travel & lodging$1,5932%
- Food & beverage$9,99412%
- Education$7,1149%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$64,670
- Da Vinci Surgical System$4,000
- ION$3,000
- Photofrin$300
How this compares
$80,526 in reported general payments places this provider in the 90th percentile of 192 pulmonary disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 70 | $899,706 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 622 | $521,416 |
| Tyvaso DpiTreprostinil | 13 | $305,043 |
| OpsumitMacitentan | 24 | $303,132 |
| UptraviSelexipag | 13 | $291,230 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 219 | $153,735 |
| Fasenra PenBenralizumab | 11 | $68,371 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 134 | $64,594 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 72 | $37,597 |
| Spiriva RespimatTiotropium Bromide | 48 | $34,333 |
| Breo ElliptaFluticasone/Vilanterol | 54 | $25,424 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 585 | $17,660 |
| SymbicortBudesonide/Formoterol Fumarate | 39 | $15,677 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 41 | $6,309 |
| Wixela InhubFluticasone Propion/Salmeterol | 47 | $4,044 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $784 | $971,636190 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $1,015 | $611,434810 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $331 | $594,36237 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $67,064 | $169,412258 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 192 pulmonary disease providers in South Carolina.
Other pulmonary disease in Anderson
- Abhijit RavalAnderson$2M
- Charles ThompsonAnderson$24K
- Syed MalikAnderson$10K
- Emerald Rose BranchAnderson$8K
- Richard BoganColumbia$1.1M
- Joseph BosciaSpartanburg$701K
- Patrick FlumeCharleston$418K
- Sean CallahanGreenville$321K
- Laura HerpelColumbia$254K
- Gerard SilvestriCharleston$254K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.